X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2374) 2374
Newsletter (201) 201
Publication (116) 116
Book Review (42) 42
Magazine Article (8) 8
Book Chapter (6) 6
Newspaper Article (6) 6
Dissertation (5) 5
Conference Proceeding (3) 3
Paper (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
candesartan (1952) 1952
humans (1054) 1054
male (803) 803
index medicus (764) 764
hypertension (693) 693
female (615) 615
candesartan cilexetil (555) 555
middle aged (470) 470
aged (456) 456
hypertension - drug therapy (417) 417
peripheral vascular disease (415) 415
pharmacology & pharmacy (406) 406
benzimidazoles - therapeutic use (380) 380
heart failure (370) 370
angiotensin (362) 362
cardiac & cardiovascular systems (362) 362
animals (357) 357
tetrazoles - therapeutic use (352) 352
mortality (347) 347
losartan (343) 343
blood pressure - drug effects (309) 309
antihypertensive agents - therapeutic use (294) 294
benzimidazoles - pharmacology (277) 277
angiotensin ii type 1 receptor blockers - therapeutic use (269) 269
treatment outcome (267) 267
valsartan (260) 260
drug therapy (259) 259
tetrazoles - pharmacology (252) 252
rats (246) 246
adult (231) 231
angiotensin receptor antagonists (215) 215
blood-pressure (214) 214
research (198) 198
risk factors (198) 198
angiotensin-converting enzyme inhibitors - therapeutic use (197) 197
blood pressure (195) 195
heart failure - drug therapy (192) 192
care and treatment (189) 189
benzimidazoles - administration & dosage (186) 186
drug therapy, combination (186) 186
morbidity (178) 178
tetrazoles - administration & dosage (177) 177
medicine, general & internal (166) 166
diabetes (165) 165
analysis (161) 161
angiotensin ii (157) 157
double-blind method (157) 157
renin-angiotensin system (154) 154
hypertension - physiopathology (153) 153
trial (153) 153
angiotensin ii type 1 receptor blockers - pharmacology (151) 151
antihypertensive agents - pharmacology (150) 150
irbesartan (144) 144
stroke (140) 140
enalapril (139) 139
aged, 80 and over (134) 134
double-blind (133) 133
dosage and administration (128) 128
biphenyl compounds - therapeutic use (127) 127
medicine & public health (127) 127
antihypertensive agents - administration & dosage (125) 125
dose-response relationship, drug (125) 125
hydrochlorothiazide (124) 124
angiotensin ii type 1 receptor blockers - administration & dosage (119) 119
telmisartan (119) 119
benzimidazoles - adverse effects (118) 118
ventricular systolic function (117) 117
randomized controlled trials as topic (116) 116
angiotensin-ii (115) 115
converting-enzyme-inhibitors (115) 115
prevention (115) 115
prognosis (112) 112
chronic heart-failure (111) 111
randomized-trial (109) 109
ace inhibitors (108) 108
cardiac patients (108) 108
heart failure - mortality (107) 107
heart failure - physiopathology (107) 107
tetrazoles - adverse effects (107) 107
follow-up studies (106) 106
health aspects (106) 106
tetrazoles (106) 106
clinical trials (102) 102
heart-failure (102) 102
medical research (102) 102
time factors (102) 102
risk (101) 101
converting-enzyme inhibitors (99) 99
internal medicine (99) 99
angiotensin ii receptor blockers (98) 98
management (98) 98
myocardial-infarction (98) 98
antihypertensive agents - adverse effects (97) 97
renin-angiotensin system - drug effects (97) 97
medicine (96) 96
therapy (96) 96
prospective studies (93) 93
expression (91) 91
amlodipine (90) 90
hypertension - complications (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2477) 2477
German (32) 32
Russian (23) 23
Japanese (20) 20
Spanish (18) 18
French (12) 12
Czech (5) 5
Hungarian (2) 2
Persian (2) 2
Portuguese (2) 2
Chinese (1) 1
Korean (1) 1
Polish (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Experimental Hypertension, ISSN 1064-1963, 11/2019, Volume 41, Issue 8, pp. 747 - 752
BACKGROUND: We hypothesized that the 5-oxo-1,2,4-oxadiazole moiety of azilsartan (AZL), which represents a small difference in the molecular structures of AZL... 
5-oxo-1-oxadiazole | Arg | azilsartan | candesartan
Journal Article
Journal of Biochemical and Molecular Toxicology, ISSN 1095-6670, 03/2019, Volume 33, Issue 3
This study pointed to estimate the possible protective impacts of candesartan and/or epigallocatechin-3-gallate (EGCG) against gentamicin-induced... 
Catechin | Candesartan | Aminoglycosides | Mitogens
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 11/2019, p. 111848
Journal Article
Acta Pharmaceutica, ISSN 1330-0075, 03/2019, Volume 69, Issue 1, pp. 63 - 74
Development of safe and effective drugs requires complete impurity evaluation and, therefore, knowledge about the formation and elimination of impurities is... 
synthesis | HRMS | candesartan cilexetil (TCV-116) | impurity | diastereoisomers | candesartan cilexetil ( TCV-116) | PHARMACOLOGY & PHARMACY | Candesartan cilexetil | Target recognition | Nuclear magnetic resonance--NMR | Synthesis | Impurities | Imidazole | Analyzers | Biphenyl | Liquid chromatography | Drug development | Carbonyls
Journal Article
Brain Research, ISSN 0006-8993, 07/2000, Volume 871, Issue 1, pp. 29 - 38
Brain Angiotensin II, through stimulation of brain AT sub(1) receptors, regulates pituitary hormones and autonomic activity. We have administered the... 
Candesartan
Journal Article
Asian Journal of Pharmaceutics, ISSN 0973-8398, 07/2018, Volume 12, Issue 3, pp. 196 - 203
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2013, Volume 34, Issue 19, pp. 1404 - 1413
Using a large international database from multiple cohort studies, the aim is to create a generalizable easily used risk score for mortality in patients with... 
Heart failure | Prognostic model | Mortality | Meta-analysis | VENTRICULAR EJECTION FRACTION | CARDIAC & CARDIOVASCULAR SYSTEMS | MODEL | TRIAL | DISCHARGE | MORBIDITY | CANDESARTAN | SYSTOLIC DYSFUNCTION | PROGRAM | Female | Male | Epidemiologic Methods | Humans | Middle Aged | Heart Failure - mortality
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 08/2018, Volume 20, Issue 8, pp. 1240 - 1242
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 2011, Volume 149, Issue 2, pp. 168 - 174
Journal Article
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 04/2015, Volume 140, pp. 210 - 215
Two different methods manipulating spectrophotometric data have been developed, validated and compared. One is capable of removing the signal of any... 
Hydrochlorothiazide | Irbesartan | Spectrophotometry | Candesartan | MCR | CRACLS | SPECTROSCOPY | SPECTROPHOTOMETRIC METHOD | BINARY | CANDESARTAN CILEXETIL | HPLC
Journal Article
Bioorganic and Medicinal Chemistry, ISSN 0968-0896, 12/2009, Volume 17, Issue 23, pp. 7971 - 7977
[ C]Methyl-candesartan and its desethyl derivative ([ C]TH4) were developed as potential radiotracers for imaging angiotensin II (Ang II) type 1 (AT )... 
C]Desethyl-candesartan | C]Methyl-candesartan | PET imaging | C]Radiolabeling
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 05/2015, Volume 3, Issue 5, pp. 316 - 316
Journal Article
Drug Development and Industrial Pharmacy, ISSN 0363-9045, 07/2019, Volume 45, Issue 7, pp. 1140 - 1148
The objective of this study was to improve candesartan cilexetil (CC) efficacy by formulating nanocrystals via solid dispersion (SD) technique using... 
prodrug | tromethamine | Candesartan | solid dispersion | bioavailability | candesartan cilexetil | VITRO | LIPID NANOPARTICLES | CHEMISTRY, MEDICINAL | WATER-SOLUBLE DRUG | FORMULATION | MELT EXTRUDATE | ENHANCED DISSOLUTION | RELEASE MECHANISM | TABLETS | ORAL BIOAVAILABILITY | PHARMACOLOGY & PHARMACY | ABSORPTION
Journal Article
Obstetrics & Gynecology, ISSN 0029-7844, 09/2019, Volume 134, Issue 3, pp. 481 - 484
BACKGROUND:There are currently no data regarding the transfer of candesartan into human milk. This report provides data on this transfer, an estimation of the... 
Candesartan | Physiological aspects | Drug therapy | Mothers | Health aspects | Contamination | Breast milk
Journal Article
by Berry, C and Doughty, RN and Granger, C and Kober, L and Massie, B and McAlister, F and McMurray, J and Pocock, S and Poppe, K and Swedberg, K and Somaratne, J and Whalley, GA and Ahmed, A and Andersson, B and Bayes-Genis, A and Cowie, M and Cubbon, R and Ezekowitz, J and Gonzalez-Juanatey, J and Gorini, M and Gotsman, I and Grigorian-Shamagian, L and Guazzi, M and Kearney, M and Komajda, M and di Lenarda, A and Lenzen, M and Lucci, D and Macin, S and Madsen, B and Maggioni, A and Martinez-Selles, M and Oliva, F and Rich, M and Richards, M and Senni, M and Squire, I and Taffet, G and Tarantini, L and Tribouilloy, C and Troughton, R and Tsutsui, H and Earle, N and Perera, K and Dobson, J and Whalley, G and Hall, C and Richards, AM and Lainchbury, J and Hogg, K and Norrie, J and Stevenson, K and Brett, M and Pfeffer, MA and Granger, CB and Held, P and McMurray, JJV and Michelson, EL and Olofsson, B and Ostergren, J and Yusuf, S and Torp-Pedersen, C and Lenzen, MJ and Reimer, WJMS and Boersma, E and Vantrimpont, PJMJ and Follath, F and Cleland, J and Zwas, D and Planer, D and Azaz-Livshits, T and Admon, D and Lotan, C and Keren, A and Varela-Roman, A and Mazon-Ramos, P and Rigeiro-Veloso, P and Bandin-Dieguez, MA and Gonzalez-Juanatey, JR and Myers, J and Arena, R and McAlister, FA and Armstrong, PW and Cujec, B and Paterson, I and Cowie, MR and Wood, DA and Coats, AJS and Thompson, SG and Suresh, V and Poole-Wilson, PA and Sutton, GC and Robles, JAG and Prieto, L and Munoa, MD and Frades, E and Diaz-Castro, O and Almendral, J and Faggiano, P and Bertoli, D and ... and MAGGIC Coordinating Ctr and MAGGIC Stat Grp and MAGGIC Studies & Investigators and CHARM Investigators & Comm and Meta-Anal Global Grp Chronic Heart and MAGGIC Steering Grp and Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 07/2012, Volume 33, Issue 14, pp. 1750 - 1757
Journal Article
European Heart Journal, ISSN 0195-668X, 6/2008, Volume 29, Issue 11, pp. 1377 - 1385
Aims To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection... 
VENTRICULAR SYSTOLIC DYSFUNCTION | MORTALITY | heart failure | CAPACITY | CARDIAC & CARDIOVASCULAR SYSTEMS | ABNORMALITIES | CLINICAL CHARACTERISTICS | MELLITUS | MORBIDITY | CANDESARTAN | diabetes | ASSOCIATION | PROGRAM
Journal Article
by Saglimbene, Valeria and Palmer, Suetonia C and Ruospo, Marinella and Natale, Patrizia and Maione, Ausilia and Nicolucci, Antonio and Vecchio, Mariacristina and Tognoni, Gianni and Craig, Jonathan C and Pellegrini, Fabio and Lucisano, Giuseppe and Hegbrant, Jörgen and Ariano, Rosario and Lamacchia, Olga and Sasso, Antonio and Morano, Susanna and Filardi, Tiziana and De Cosmo, Salvatore and Pugliese, Giuseppe and Procaccini, Deni A and Gesualdo, Loreto and Palasciano, Giuseppe and Johnson, David W and Tonelli, Marcello and Strippoli, Giovanni F.M and Cignarelli, Mauro and Di Mauro, Maurizio and Tonolo, Giancarlo and Adinolfi, Luigi Elio and Gigante, Alfonso and Carboni, Luciano and Anichini, Roberto and Marino, Cecilia and Querques, Mario and Manfrini, Silvana and Cianciaruso, Bruno and Grandaliano, Giuseppe and Prato, Stefano Del and Giorgino, Francesco and Perin, Paolo Cavallo and Malberti, Fabio and Nardo, Alfio and Invitti, Cecilia and Panettieri, Immacolata and Bono-mini, Mario and Sesti, Giorgio and Altomare, Emanuele and Giordano, Rosa and Iacono, Alessandro and Lusenti, Tiziano and Jovane, Carlo and Zavaroni, Ivana and Vernaglione, Luigi and Grosso, Juliette and Stratta, Piero and Andriani, Antonia and Montanaro, Alessio and Ciaula, Agostino Di and Triolo, Giorgio and Santoro, Antonio and Spada, Silvio and Benedetto, Antonio Di and Borzì, Vito and Tortul, Carla and Schiavoni, Mario and Cavalera, Cesare and Iannarelli, Rossella and Mileti, Giovanni and Tardi, Salvatore and Di Rosa, Salvatore and Long-Term Impact RAS and Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators and on behalf of the Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators
Journal of the American Society of Nephrology, ISSN 1046-6673, 12/2018, Volume 29, Issue 12, pp. 2890 - 2899
Background The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their... 
TELMISARTAN | RAMIPRIL | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | RISK | CANDESARTAN | TYPE-2 | BLOOD-PRESSURE | ENALAPRIL | VALSARTAN
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.